Key points are not available for this paper at this time.
We describe distinct clinical outcomes and recurrence rates associated with meningioma molecular subgroups. Our findings emphasize the importance of genomic characterization to guide postoperative management decisions for meningiomas.
Youngblood et al. (Mon,) studied this question.